Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""angiogenesis"" wg kryterium: Temat


Starter badań:

Tytuł :
Class-3 semaphorins: Potent multifunctional modulators for angiogenesis-associated diseases.
Autorzy :
Jiao B; Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Liu S; Department of Thyroid and Breast Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Tan X; Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Lu P; Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Wang D; Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Xu H; Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 May; Vol. 137, pp. 111329. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiogenesis Modulating Agents*
Neovascularization, Pathologic/*genetics
Semaphorins/*genetics
Angiogenesis Inducing Agents/pharmacology ; Angiogenesis Inhibitors/pharmacology ; Animals ; Humans ; Signal Transduction
Czasopismo naukowe
Tytuł :
The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids.
Autorzy :
Truelsen SLB; 2cureX, Symbion, Copenhagen, Denmark.
Mousavi N; Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Wei H; School of Biochemistry, University of Bristol, Bristol, United Kingdom.
Harvey L; School of Biochemistry, University of Bristol, Bristol, United Kingdom.
Stausholm R; 2cureX, Symbion, Copenhagen, Denmark.
Spillum E; BioSense Solutions, Farum, Denmark.
Hagel G; 2cureX, Symbion, Copenhagen, Denmark.
Qvortrup K; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Thastrup O; 2cureX, Symbion, Copenhagen, Denmark.
Harling H; 2cureX, Symbion, Copenhagen, Denmark.; Department of Digestive Diseases, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Mellor H; School of Biochemistry, University of Bristol, Bristol, United Kingdom.
Thastrup J; 2cureX, Symbion, Copenhagen, Denmark.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2021 Jul 07; Vol. 16 (7), pp. e0253258. Date of Electronic Publication: 2021 Jul 07 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*pharmacology
Coculture Techniques/*methods
Neovascularization, Pathologic/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inducing Agents/pharmacology ; Cell Line, Tumor ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Female ; Fibroblast Growth Factors/pharmacology ; Fibroblasts/drug effects ; Human Umbilical Vein Endothelial Cells/drug effects ; Humans ; In Vitro Techniques ; Male ; Middle Aged ; Platelet-Derived Growth Factor/pharmacology ; Spheroids, Cellular/drug effects ; Vascular Endothelial Growth Factor A/pharmacology
Czasopismo naukowe
Tytuł :
Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.
Autorzy :
Song J; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Guan Z; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Song C; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Li M; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Gao Z; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Zhao Y; Department of Radiotherapy, Qingdao Jiaozhou City Central Hospital, Jiaozhou, Qingdao 266300, P.R. China.
Pokaż więcej
Źródło :
Molecular medicine reports [Mol Med Rep] 2021 Jun; Vol. 23 (6). Date of Electronic Publication: 2021 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inducing Agents/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Cell Movement/*drug effects
Liver Neoplasms/*drug therapy
Pyridines/*pharmacology
Receptors, Vascular Endothelial Growth Factor/*drug effects
Angiogenesis Inhibitors/pharmacology ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Gene Expression Regulation, Neoplastic ; Humans ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Receptors, Vascular Endothelial Growth Factor/metabolism ; Signal Transduction ; Vascular Endothelial Growth Factor Receptor-2/metabolism ; Wound Healing/genetics
Czasopismo naukowe
Tytuł :
Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Autorzy :
Wang S; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhang RH; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Zhang H; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Wang YC; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yang D; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhao YL; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yan GY; Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Henan University, Zhengzhou, PR China.
Xu GB; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Guan HY; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhou YH; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Cui DB; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Liu T; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Li YJ; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Liao SG; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .
Zhou M; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113573. Date of Electronic Publication: 2021 May 29.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Angiogenesis Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Focal Adhesion Kinase 1/*antagonists & inhibitors
Neovascularization, Pathologic/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Angiogenesis Inhibitors/chemical synthesis ; Angiogenesis Inhibitors/chemistry ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Focal Adhesion Kinase 1/metabolism ; Humans ; Molecular Structure ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Mechanism Analysis of Antiangiogenic d-Isofloridoside from Marine Edible Red algae Laurencia undulata in HUVEC and HT1080 cell.
Autorzy :
Yang S; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.; Key Laboratory of Tropical Crop Products Processing of Ministry of Agriculture and Rural Affairs, Agricultural Products Processing Research Institute, Chinese Academy of Tropical Agricultural Sciences, Zhanjiang 524001, China.
Xiao Z; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.
Lin L; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.
Tang Y; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.
Hong P; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.; Southern Marine Science and Engineering Guangdong Laboratory, Zhanjiang 524025, China.
Sun S; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.
Zhou C; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.; Southern Marine Science and Engineering Guangdong Laboratory, Zhanjiang 524025, China.
Qian ZJ; College of Food Science and Technology, School of Chemistry and Environment, Shenzhen Institute of Guangdong Ocean University, Guangdong Ocean University, Zhanjiang, Guangdong 524088, China.; Southern Marine Science and Engineering Guangdong Laboratory, Zhanjiang 524025, China.
Pokaż więcej
Źródło :
Journal of agricultural and food chemistry [J Agric Food Chem] 2021 Nov 24; Vol. 69 (46), pp. 13787-13795. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors*/pharmacology
Laurencia*
Endothelial Cells ; Galactosides ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Proto-Oncogene Proteins c-akt/genetics ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł :
An updated patent review of VEGFR-2 inhibitors (2017-present).
Autorzy :
Farghaly TA; Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.; Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia.
Al-Hasani WA; Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia.
Abdulwahab HG; Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Pokaż więcej
Źródło :
Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2021 Nov; Vol. 31 (11), pp. 989-1007. Date of Electronic Publication: 2021 Jun 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiogenesis Inhibitors/*pharmacology
Neovascularization, Pathologic/*drug therapy
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
Angiogenesis Inhibitors/adverse effects ; Animals ; Humans ; Neoplasms/blood supply ; Neoplasms/drug therapy ; Neovascularization, Pathologic/pathology ; Patents as Topic ; Signal Transduction/drug effects ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Tytuł :
The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Autorzy :
Shigemoto Y; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan.
Sakurada Y; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan.
Fukuda Y; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan.
Matsubara M; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan.
Parikh R; Manhattan Retina and Eye Consultants, New York, NY.; New York University Grossman School of Medicine, New York, NY.
Kashiwagi K; Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Oct 22; Vol. 100 (42), pp. e27580.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Triamcinolone Acetonide/*therapeutic use
Wet Macular Degeneration/*drug therapy
Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Drug Therapy, Combination ; Humans ; Intravitreal Injections ; Male ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Subretinal Fluid ; Triamcinolone Acetonide/administration & dosage ; Visual Acuity
Czasopismo naukowe
Tytuł :
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
Autorzy :
Tang B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Mo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Yan X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Duan R; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Chi Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Si L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Kong Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Mao L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Li S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Zhou L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Lian B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Bai X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Xu H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Li C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Dai J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Oct; Vol. 156, pp. 83-92. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Axitinib/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Melanoma/*drug therapy
Mucous Membrane/*drug effects
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Axitinib/adverse effects ; Drug Synergism ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Male ; Melanoma/immunology ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Mucous Membrane/immunology ; Mucous Membrane/pathology ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Autorzy :
Eto T; Clinical Research Unit, Souseikai Hakata Clinic, Fukuoka, Japan.
Karasuyama Y; Syneos Health Clinical K.K., Tokyo, Japan.
González V; Medical Department, mAbxience Research S.L., Madrid, Spain.
Del Campo García A; Medical Department, mAbxience Research S.L., Madrid, Spain. .
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Oct; Vol. 88 (4), pp. 713-722. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*pharmacokinetics
Bevacizumab/*pharmacokinetics
Biosimilar Pharmaceuticals/*pharmacokinetics
Adult ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Area Under Curve ; Asian Continental Ancestry Group ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Biosimilar Pharmaceuticals/administration & dosage ; Biosimilar Pharmaceuticals/adverse effects ; Double-Blind Method ; Humans ; Male ; Young Adult
Czasopismo naukowe
Tytuł :
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Autorzy :
Erman M; Medical Oncology, Hacettepe University, Ankara, Turkey.
Biswas B; Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
Danchaivijitr P; Medical Oncology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chen L; Medical Oncology, The First Affiliated Hospital of Sun Yat-sen, Guangzhou, Guangdong Province, China.
Wong YF; Radiotherapy and Oncology, National Cancer Institute, Putrajaya, Malaysia.
Hashem T; Medical Oncology, Dr Tarek Hashem's Clinic, Cairo, Egypt.
Lim CS; Clinical Oncology, Sultan Ismail Hospital, Johor Bahru, Malaysia.
Karabulut B; Medical Oncology, Ege University, Izmir, Turkey.
Chung HJ; Department of Urology, Taipei Veterans General Hospital and Department of Urology, College of Medicine and Shu-Tien Urological Research Cente, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chikatapu C; Oncology, Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India.
Ingles S; Oncology, Novartis Pharma AG, Basel, Switzerland.
Slimane K; Oncology, Novartis Pharma SAS, Rueil-Malmaison, France.
Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Sep 14; Vol. 21 (1), pp. 1021. Date of Electronic Publication: 2021 Sep 14.
Typ publikacji :
Clinical Trial, Phase IV; Journal Article; Observational Study
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Indazoles/*therapeutic use
Kidney Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Sulfonamides/*therapeutic use
Adult ; Africa, Northern ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Asia ; Carcinoma, Renal Cell/ethnology ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Female ; Humans ; Indazoles/administration & dosage ; Indazoles/adverse effects ; Kidney Neoplasms/ethnology ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Middle East ; Progression-Free Survival ; Prospective Studies ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Response Evaluation Criteria in Solid Tumors ; Risk Factors ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2A-Smad2/3 in rats following myocardial infarction.
Autorzy :
Xi Y; Institute of Sports and Exercise Biology, Shaanxi Normal University, Xi'an 710119, China.
Hao M; Institute of Sports and Exercise Biology, Shaanxi Normal University, Xi'an 710119, China; School of Physical Education, Luoyang Normal University, Luoyang 471934, China.
Liang Q; Institute of Sports and Exercise Biology, Shaanxi Normal University, Xi'an 710119, China.
Li Y; School of Life Science, Shaanxi Normal University, Xi'an 710119, China.
Gong DW; Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Tian Z; Institute of Sports and Exercise Biology, Shaanxi Normal University, Xi'an 710119, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of sport and health science [J Sport Health Sci] 2021 Sep; Vol. 10 (5), pp. 594-603. Date of Electronic Publication: 2020 Nov 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inducing Agents*
Follistatin-Related Proteins/*pharmacology
Myocardial Infarction/*therapy
Nuclear Proteins/*metabolism
Physical Conditioning, Animal/*methods
Smad2 Protein/*metabolism
Smad3 Protein/*metabolism
Animals ; Disease Models, Animal ; Male ; Muscle, Skeletal/metabolism ; Rats ; Rats, Sprague-Dawley ; Up-Regulation
Czasopismo naukowe
Tytuł :
One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy.
Autorzy :
Rouvas A; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Gouliopoulos N; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Douvali M; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Koutsocheras G; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Theodorou M; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Bouratzis N; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Bougatsou P; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Theodossiadis P; Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Pokaż więcej
Źródło :
European journal of ophthalmology [Eur J Ophthalmol] 2021 Nov; Vol. 31 (6), pp. 2868-2875. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors*/therapeutic use
Receptors, Vascular Endothelial Growth Factor*
Follow-Up Studies ; Humans ; Intravitreal Injections ; Prospective Studies ; Recombinant Fusion Proteins ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Impact of a more stringent organization of intravitreal injection treatment on the number of treatments and examinations in routine practice].
Autorzy :
Glück S; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland. .
Brandlhuber U; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Gerbutavicius R; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Kortüm GF; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Kortüm I; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Navarrete Orozco R; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Rakitin M; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Strodtbeck M; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.
Kortüm K; Augenarztpraxis Dres. Kortüm, Solitudestr. 24, 71638, Ludwigsburg, Deutschland.; Augenklinik, Universität München, München, Deutschland.
Pokaż więcej
Transliterated Title :
Auswirkungen einer stringenteren IVOM-Behandlungsorganisation auf die Anzahl der Behandlungen und Untersuchungen im Praxisalltag.
Źródło :
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft [Ophthalmologe] 2021 Nov; Vol. 118 (11), pp. 1134-1139. Date of Electronic Publication: 2020 Nov 30.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors*/therapeutic use
Ranibizumab*
Follow-Up Studies ; Humans ; Intravitreal Injections ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Curcuma-Based Nutritional Supplement in Patients with Neovascular Age-Related Macular Degeneration.
Autorzy :
Allegrini D; Eye Center, Humanitas, Bergamo, Italy.; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
Raimondi R; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
Angi M; National Cancer Institute IRCCS Foundation, Milan, Italy.
Ricciardelli G; Eye Center, Humanitas, Bergamo, Italy.
Montericcio A; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
Borgia A; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
Romano MR; Eye Center, Humanitas, Bergamo, Italy.; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
Pokaż więcej
Źródło :
Journal of medicinal food [J Med Food] 2021 Nov; Vol. 24 (11), pp. 1191-1196. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors*
Wet Macular Degeneration*
Curcuma ; Humans ; Ranibizumab ; Retrospective Studies ; Vascular Endothelial Growth Factor A ; Visual Acuity
Czasopismo naukowe
Tytuł :
Comparative chemical analysis of six ancient italian sweet cherry (Prunus avium L.) varieties showing antiangiogenic activity.
Autorzy :
De Leo M; Dipartimento di Farmacia, Università di Pisa, via Bonanno 33, 56126 Pisa, Italy; Centro Interdipartimentale di Ricerca 'Nutraceutica e Alimentazione per la Salute', via del Borghetto 80, Università di Pisa, 56124 Pisa, Italy.
Iannuzzi AM; Dipartimento di Farmacia, Università di Pisa, via Bonanno 33, 56126 Pisa, Italy.
Germanò MP; Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, Università degli Studi di Messina, Polo Universitario SS Annunziata, 98168 Messina, Italy.
D'Angelo V; Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, Università degli Studi di Messina, Polo Universitario SS Annunziata, 98168 Messina, Italy.
Camangi F; Scuola Superiore Sant'Anna di Studi Universitari e di Perfezionamento, Piazza Martiri della Libertà 33, 56127 Pisa, Italy.
Sevi F; Agenzia Nazionale per le Nuove Tecnologie, l'Energia e lo Sviluppo Economico Sostenibile (ENEA), Centro Ricerche 'Casaccia', Laboratorio Biotecnologie, Roma 00123, Italy.
Diretto G; Agenzia Nazionale per le Nuove Tecnologie, l'Energia e lo Sviluppo Economico Sostenibile (ENEA), Centro Ricerche 'Casaccia', Laboratorio Biotecnologie, Roma 00123, Italy.
De Tommasi N; Dipartimento di Farmacia, Università degli Studi di Salerno, via Giovanni Paolo II 132, 84084 Fisciano, SA, Italy. Electronic address: .
Braca A; Dipartimento di Farmacia, Università di Pisa, via Bonanno 33, 56126 Pisa, Italy; Centro Interdipartimentale di Ricerca 'Nutraceutica e Alimentazione per la Salute', via del Borghetto 80, Università di Pisa, 56124 Pisa, Italy.
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2021 Oct 30; Vol. 360, pp. 129999. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Angiogenesis Inhibitors/*analysis
Plant Extracts/*chemistry
Prunus avium/*chemistry
Alkaline Phosphatase/metabolism ; Angiogenesis Inhibitors/pharmacology ; Animals ; Anthocyanins/analysis ; Antioxidants/chemistry ; Chromatography, High Pressure Liquid ; Cluster Analysis ; Embryo, Nonmammalian/diagnostic imaging ; Embryo, Nonmammalian/metabolism ; Flavonoids/analysis ; Fruit/chemistry ; Fruit/metabolism ; Italy ; Phenols/analysis ; Plant Extracts/pharmacology ; Prunus avium/metabolism ; Spectrometry, Mass, Electrospray Ionization ; Zebrafish/growth & development ; Zebrafish/metabolism
Czasopismo naukowe
Tytuł :
Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin.
Autorzy :
Hunter EJ; Department of Biochemistry, University of Cambridge, Downing Site, Cambridge CB2 1QW, UK.
Hamaia SW; Department of Biochemistry, University of Cambridge, Downing Site, Cambridge CB2 1QW, UK.
Gullberg D; Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009 Bergen, Norway.
Malcor JD; Department of Biochemistry, University of Cambridge, Downing Site, Cambridge CB2 1QW, UK.
Farndale RW; Department of Biochemistry, University of Cambridge, Downing Site, Cambridge CB2 1QW, UK. Electronic address: .
Pokaż więcej
Źródło :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2021 Oct 01; Vol. 428, pp. 115669. Date of Electronic Publication: 2021 Aug 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*pharmacology
Collagen/*metabolism
Integrin alpha2beta1/*antagonists & inhibitors
Integrin alpha2beta1/*metabolism
Viper Venoms/*metabolism
Viper Venoms/*pharmacology
Angiogenesis Inhibitors/chemistry ; Animals ; Cell Adhesion/drug effects ; Cell Adhesion/physiology ; Cell Line ; Dose-Response Relationship, Drug ; Mice ; Protein Binding/drug effects ; Protein Binding/physiology
Czasopismo naukowe
Tytuł :
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
Autorzy :
Marlow N; UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK. Electronic address: .
Stahl A; Department of Ophthalmology, University Medical Center Greifswald, Greifswald, Germany.
Lepore D; Department of Ophthalmology, Gemelli Foundation IRCSS, Catholic University of the Sacred Heart, Rome, Italy.
Fielder A; Department of Optometry and Visual Science, City, University of London, London, UK.
Reynolds JD; Ross Eye Institute, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Zhu Q; China Novartis Institutes for BioMedical Research Company, Shanghai, China.
Weisberger A; Ophthalmology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Stiehl DP; Novartis Pharma, Basel, Switzerland.
Fleck B; Royal Hospital for Sick Children, University of Edinburgh, Edinburgh, UK.
Pokaż więcej
Corporate Authors :
RAINBOW investigators group
Źródło :
The Lancet. Child & adolescent health [Lancet Child Adolesc Health] 2021 Oct; Vol. 5 (10), pp. 698-707. Date of Electronic Publication: 2021 Aug 13.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Laser Therapy*
Angiogenesis Inhibitors/*administration & dosage
Ranibizumab/*administration & dosage
Retinopathy of Prematurity/*therapy
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Angiogenesis Inhibitors/adverse effects ; Child, Preschool ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Infant ; Infant, Very Low Birth Weight ; Intravitreal Injections ; Male ; Prospective Studies ; Quality of Life ; Ranibizumab/adverse effects ; Visual Acuity
Czasopismo naukowe
Tytuł :
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Autorzy :
Valle JW; Division of Cancer Sciences and Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. Electronic address: .
Vogel A; Hannover Medical School, Hannover, Germany.
Denlinger CS; Fox Chase Cancer Center, Philadelphia, PA, USA.
He AR; Georgetown University Medical Center, Washington, DC, USA.
Bai LY; China Medical University Hospital, China Medical University, Taichung, Taiwan.
Orlova R; China Medical University Hospital, China Medical University, Taichung, Taiwan.
Van Cutsem E; University Hospital Gasthuisberg and KU Leuven, Leuven, Belgium.
Adeva J; University Hospital 12 de Octubre, Madrid, Spain.
Chen LT; National Health Research Institutes, Miaoli, Taiwan.
Obermannova R; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Ettrich TJ; Ulm University Hospital, Ulm, Germany.
Chen JS; Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.
Wasan H; Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Girvan AC; Eli Lilly and Company, Indianapolis, IN, USA.
Zhang W; Eli Lilly and Company, Indianapolis, IN, USA.
Liu J; Eli Lilly and Company, Indianapolis, IN, USA.
Tang C; Eli Lilly and Company, Indianapolis, IN, USA.
Ebert PJ; Eli Lilly and Company, Indianapolis, IN, USA.
Aggarwal A; Eli Lilly and Company, Indianapolis, IN, USA.
McNeely SC; Eli Lilly and Company, Indianapolis, IN, USA.
Moser BA; Eli Lilly and Company, Indianapolis, IN, USA.
Oliveira JM; Eli Lilly and Company, New York, NY, USA.
Carlesi R; Eli Lilly and Company, Sesto Fiorentino, Florence, Italy.
Walgren RA; Eli Lilly and Company, Indianapolis, IN, USA.
Oh DY; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1468-1482.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Angiogenesis Inhibitors/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biliary Tract Neoplasms/*drug therapy
Indazoles/*administration & dosage
Niacinamide/*analogs & derivatives
Protein Kinase Inhibitors/*administration & dosage
Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biliary Tract Neoplasms/mortality ; Biliary Tract Neoplasms/pathology ; Disease Progression ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Indazoles/adverse effects ; Male ; Middle Aged ; Niacinamide/administration & dosage ; Niacinamide/adverse effects ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Time Factors
Czasopismo naukowe
Tytuł :
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Autorzy :
Pinto C; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Zucali PA; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy. Electronic address: .
Pagano M; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Grosso F; Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Infrastruttura Ricerca Formazione e Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Pasello G; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
Garassino MC; Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tiseo M; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Soto Parra H; Medical Oncology Unit, AOU Policlinico Vittorio Emanuele, Catania, Italy.
Grossi F; Medical Oncology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore, Milan, Italy; Medical Oncology Unit, University of Insubria, Varese, Italy.
Cappuzzo F; Medical Oncology Unit, IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
de Marinis F; Thoracic Oncology Division, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
Bonomi M; Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy; Department of Oncology, ASST Cremona, Cremona, Italy.
Gianoncelli L; Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy; Department of Oncology, Ospedale San Paolo, Milan, Italy.
Perrino M; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
Santoro A; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
Zanelli F; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Bonelli C; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Maconi A; Infrastruttura Ricerca Formazione e Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Frega S; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
Gervasi E; Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Boni L; Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Ceresoli GL; Department of Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1438-1447. Date of Electronic Publication: 2021 Sep 06.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Deoxycytidine/*analogs & derivatives
Mesothelioma, Malignant/*drug therapy
Pleural Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Italy ; Male ; Mesothelioma, Malignant/diagnosis ; Mesothelioma, Malignant/mortality ; Middle Aged ; Pleural Neoplasms/diagnosis ; Pleural Neoplasms/mortality ; Progression-Free Survival ; Time Factors
Czasopismo naukowe
Tytuł :
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Autorzy :
Kriston C; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Hernádfői M; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Plander M; Department of Hematology, Markusovszky University Teaching Hospital, Szombathely, Hungary.
Márk Á; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Takács F; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Czeti Á; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Szalóki G; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Szabó O; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Matolcsy A; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Barna G; Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 513-520. Date of Electronic Publication: 2021 May 20.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Bone Marrow/*metabolism
Lenalidomide/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/pharmacology ; Female ; Humans ; Lenalidomide/pharmacology ; Male ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies